Ata uhi

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

<p>So far, in the advanced non-small cell lung cancer (NSCLC) with clear epidermal growth factor receptor (EGFR) gene status, the treatment remmendations has reached an agreement: for patients with EGFR mutation-positive, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Caixia Deng (Author), Hu Luo (Author), Xiangdong Zhou (Author)
Hōputu:	Pukapuka
I whakaputaina:	Open Journal of Cell and Protein Science - Peertechz Publications, 2018-10-01.
Ngā marau:	Case Report
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
mā: Isla D, me ētahi atu.
I whakaputaina: (2016)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
mā: Yamin Shu, me ētahi atu.
I whakaputaina: (2022)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
mā: Fouad Al Dayel
I whakaputaina: (2012)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
mā: Walleser S, me ētahi atu.
I whakaputaina: (2012)

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
mā: Cong Xu, me ētahi atu.
I whakaputaina: (2023)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
mā: M. Yoon, me ētahi atu.
I whakaputaina: (2016)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
mā: Federica Pecci, me ētahi atu.
I whakaputaina: (2022)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
mā: Haoyue Hu, me ētahi atu.
I whakaputaina: (2023)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
mā: Vergnenègre A, me ētahi atu.
I whakaputaina: (2012)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
mā: Jonathan R. Thompson, me ētahi atu.
I whakaputaina: (2016)

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
mā: Fang S, me ētahi atu.
I whakaputaina: (2014)

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
mā: Shike Yan, me ētahi atu.
I whakaputaina: (2022)

Prediction of EGFR Mutation Status in Non-Small Cell Lung Cancer Based on Ensemble Learning
mā: Youdan Feng, me ētahi atu.
I whakaputaina: (2022)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
mā: Connor O'Leary, me ētahi atu.
I whakaputaina: (2020)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma
mā: Tripti Nakra, me ētahi atu.
I whakaputaina: (2021)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
mā: A. U. Kulikov
I whakaputaina: (2015)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
mā: Togashi Y, me ētahi atu.
I whakaputaina: (2014)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
mā: Cong Wang, me ētahi atu.
I whakaputaina: (2018)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
mā: Kathleen E. Spitz, MD, MBA, me ētahi atu.
I whakaputaina: (2022)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
mā: Chen Shi, me ētahi atu.
I whakaputaina: (2023)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
mā: Jiabao Hou, me ētahi atu.
I whakaputaina: (2022)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
mā: Brian J. Thomas, me ētahi atu.
I whakaputaina: (2023)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
mā: Julie M. Janssen, me ētahi atu.
I whakaputaina: (2022)

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
mā: Shihui Bao, me ētahi atu.
I whakaputaina: (2021)

Erlotinib resistance in Lung Cancer: Current Progress and Future Perspectives
mā: Joy eTang, me ētahi atu.
I whakaputaina: (2013)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
mā: Chih-Jen Yang, me ētahi atu.
I whakaputaina: (2017)

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits
mā: Eszter Bencze, me ētahi atu.
I whakaputaina: (2022)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
mā: Keigo Kobayashi
I whakaputaina: (2023)

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells
mā: Ebony Nottingham, me ētahi atu.
I whakaputaina: (2021)

Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
mā: Otto Claudia, me ētahi atu.
I whakaputaina: (2012)

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
mā: Anyue Yin, me ētahi atu.
I whakaputaina: (2024)

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
mā: Khalid Alhazzani, me ētahi atu.
I whakaputaina: (2023)

Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC)
mā: Gautam Chauhan, me ētahi atu.
I whakaputaina: (2023)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
mā: Yujia Wang, me ētahi atu.
I whakaputaina: (2021)

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
mā: Wei Chen, me ētahi atu.
I whakaputaina: (2023)

The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line
mā: Anna Svedberg, me ētahi atu.
I whakaputaina: (2020)

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
mā: Gengwei Huo, me ētahi atu.
I whakaputaina: (2024)

Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer
mā: Xiaojuan Zhang, me ētahi atu.
I whakaputaina: (2024)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
mā: Yun Zhang, me ētahi atu.
I whakaputaina: (2021)

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
mā: Yan Lu, me ētahi atu.
I whakaputaina: (2021)